Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.60
Bid: 0.55
Ask: 0.65
Change: 0.00 (0.00%)
Spread: 0.10 (18.182%)
Open: 0.60
High: 0.00
Low: 0.00
Prev. Close: 0.60
PXS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Funding Update

28 Jul 2017 16:30

RNS Number : 4846M
Provexis PLC
28 July 2017
 

28 July 2017

 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE PROHIBITED BY ANY APPLICABLE LAW.

 

THIS ANNOUNCEMENT AMOUNTS TO A FINANCIAL PROMOTION FOR THE PURPOSES OF SECTION 21 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 ('FSMA') AND HAS BEEN APPROVED BY DARWIN STRATEGIC LIMITED WHICH IS AUTHORISED AND REGULATED BY THE FINANCIAL CONDUCT AUTHORITY. PRIMARYBID LTD IS AN APPOINTED REPRESENTATIVE OF DARWIN STRATEGIC LIMITED.

 

 

Provexis plc

 

Funding update and fundraising via PrimaryBid

 

Provexis plc ('Provexis' or the 'Company'), the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, is pleased to announce a funding update, and a fundraising to individual and institutional investors exclusively on PrimaryBid.com from 4.30pm on 28 July 2017 to 5:00pm on 30 July 2017.

 

First Subscription - completed in May 2017

The Company confirmed in its results of placing announcement on 10 May 2017 that it had raised gross proceeds of £350,000 at 0.50 pence per ordinary share via a placing (the 'First Subscription') of 70,000,000 new ordinary shares of 0.1p each (the 'First Subscription New Ordinary Shares') with new and existing investors.

 

Second Subscription - completion expected on 31 July 2017

The Company's funding update RNS announcement of 3 July 2017 confirmed that the Company was in late stage discussions with a small group of investors in relation to a Second Subscription to raise further working capital for the Company via a placing of new ordinary shares of 0.1p each (the 'Second Subscription New Ordinary Shares'), in connection with which the Company had applied to Her Majesty's Revenue and Customs ('HMRC') for advance assurance that it would be eligible to issue new ordinary shares under HMRC's Enterprise Investment Scheme ('EIS'). The Company confirmed in its announcement of 3 July 2017 that it had received a new positive EIS advance assurance clearance from HMRC.

 

The Company is pleased to confirm a Second Subscription to raise approximately £240,000 at a subscription price of 0.50 pence per ordinary share with no commissions or expenses payable. The Company highly values its private investor base and believes it would be appropriate to provide private investors with an opportunity to participate in the Second Subscription at 0.50 pence per ordinary share by way of an offer through the Company's existing access to the PrimaryBid.com platform (the 'Offer').

 

The Company is therefore opening the Second Subscription to individual and institutional investors exclusively on PrimaryBid.com from 4:30pm today until 5:00pm on 30 July 2017. PrimaryBid Limited is acting as sole arranger for the Offer.

 

Subscriptions through the PrimaryBid.com platform will be considered by the Company on a 'first come, first served' basis subject to conditions, with any investment request over £40,000 first requiring the Company's consent.

 

The Directors believe that subscriptions through the PrimaryBid.com platform should be eligible (subject to the individual circumstances of each investor subscribing for Second Subscription New Provexis Shares) for tax reliefs for new shareholders under the Enterprise Investment Scheme ('EIS') and for investment by Venture Capital Trusts ('VCT').

 

The Company noted in its announcement of 3 July 2017 that the November 2015 changes to the EIS rules included a restriction on existing shareholders claiming EIS relief, which means that an existing shareholder will only be able to claim relief if all of their existing shares:

 

• Were issued under EIS; or

• Are subscriber shares i.e. original shares issued by the Company on incorporation

 

The Company has obtained advance assurance from HMRC that shares in the Company represent a qualifying investment for a VCT and qualify for EIS tax reliefs. The Directors are not aware of any change in the qualifying conditions or the Company's circumstances that would prevent the Second Subscription New Provexis Shares from being eligible VCT and EIS investments on this occasion. It should be noted that receipt of advance assurance is not a guarantee that the Second Subscription New Provexis Shares will qualify as a qualifying investment for a VCT or qualify for EIS tax reliefs.

 

No commission is charged to investors on applications to participate in the Offer made through PrimaryBid. It is vital to note that once an application for Second Subscription New Ordinary Shares has been made and accepted via PrimaryBid, an application cannot be withdrawn.

 

For further information on PrimaryBid.com or the procedure for applications under the Offer, please visit www.PrimaryBid.com or call PrimaryBid.com on +44 (0)20 7491 6519.

 

The Second Subscription is expected to be completed and the results of it announced on 31 July 2017.

 

Proceeds from the two placings will be used to provide the Company with additional working capital to support its growth plans over the coming years. The Company issued a trading update on 10 May 2017 at www.londonstockexchange.com/exchange/news/market-news/market-news-detail/PXS/13220035.html and a funding update on 3 July 2017 at www.londonstockexchange.com/exchange/news/market-news/market-news-detail/PXS/13280648.html . These announcements included confirmation of significant progress for the business across a number of areas.

 

Dawson Buck, Chairman of Provexis, commented:

'The Board is pleased to report that the total First and Second Subscriptions are currently expected to raise at least £590,000 in total, and the funds raised will be used to provide the Company with additional working capital to support its revenue growth plans over the coming years, to include the strongly positive announcements and initiatives which the Company set out in its recent trading update.

 

The Company highly values its private investor base and is delighted to provide private investors with an opportunity to participate in the Second Subscription at 0.50 pence per share through the PrimaryBid.com platform.'

 

This announcement contains inside information.

 

ends-

 

For further information please contact:

 

Provexis plc Tel: 07490 391888

Dawson Buck, Chairman enquiries@provexis.com

Ian Ford, Finance Director

 

Cenkos Securities plc Tel: 020 7397 8900

Bobbie Hilliam

 

PrimaryBid Limited Tel: 020 7491 6519

Dave Mutton

 

 

PrimaryBid.com Offer

The Offer is offered under the exemptions against the need for a prospectus allowed under the Prospectus Rules. As such, there is no need for publication of a prospectus pursuant to the Prospectus Rules, or for approval of the same by the Financial Conduct Authority in its capacity as the UK Listing Authority.

 

The Offer is open to existing shareholders and other investors subscribing via PrimaryBid.com. This allocation will be filled on a 'first come first served' basis.

 

The maximum investment amount under the Offer for any investor is £40,000. Any investment request over £40,000 will first require the Company's consent.

 

For further details please refer to the PrimaryBid.com website at www.PrimaryBid.com.

 

The terms and conditions on which the Offer is made, including the procedure for application and payment for Second Subscription New Ordinary Shares, is available to all persons who register with PrimaryBid.com. The Offer is made on a first come, first served basis and scale back of subscriptions (where necessary) will be made at the discretion of PrimaryBid in consultation with the Company.

 

The Company may, at its sole discretion, elect to increase the total number of Second Subscription New Ordinary Shares available under the fundraising.

 

The Second Subscription New Ordinary Shares will be issued free of all liens, charges and encumbrances and will, when issued and fully paid, rank pari passu in all respects with the existing ordinary shares of 0.1p each in Provexis.

 

Application will be made to the London Stock Exchange plc for the admission of the Second Subscription New Ordinary Shares to trading on AIM ('Admission'). It is expected that Admission will occur and that dealings will commence at 8.00 a.m. on 4 August 2017 - at which time it is also expected that the Second Subscription New Ordinary Shares will be enabled for settlement in CREST.

 

The Offer is not being made into any Restricted Jurisdiction or any other jurisdiction where it would be unlawful to do so.

 

Investors should make their own investigations into the merits of an investment in the Company. Nothing in this announcement amounts to a recommendation to invest in the Company or amounts to investment, taxation or legal advice.

 

The availability of reliefs under the EIS depends on the individual circumstances of an investor and advice should be sought by each investor on the availability of EIS reliefs for them.

 

It should be noted that a subscription for Second Subscription New Ordinary Shares and investment in the Company carries a number of risks. Investors should consider the risk factors set out on PrimaryBid.com before making a decision to subscribe for Second Subscription New Ordinary Shares. Investors should take independent advice from a person experienced in advising on investment in securities such as the Second Subscription New Ordinary Shares if they are in any doubt. 

 

Expected Timetable of Principal Events

Announcement of the Fundraising

28 July 2017

Closing of subscriptions on PrimaryBid.com

5:00 p.m. on 30 July 2017

Announcement of result of the Fundraising

31 July 2017

Admission and commencement of dealings in the Second Subscription New Ordinary Shares on AIM

By 8:00 a.m. on 4 August 2017

 

Definitions

'CREST'

the relevant system (as defined in the CREST Regulations) in respect of which Euroclear is the operator (as defined in the CREST Regulations)

'Euroclear'

Euroclear UK & Ireland Limited

'Prospectus Rules'

the Prospectus Rules made in accordance with the EU Prospectus Directive 2003/71/EC in relation to offers of securities to the public and the admission of securities to trading on a regulated market

'Restricted Jurisdictions'

United States of America, Canada, Australia, Japan and the Republic of South Africa and any other jurisdiction where the extension or availability of the Offer would breach any applicable law

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBSGDRRSDBGRI
Date   Source Headline
28th Mar 20247:00 amRNSIssue of Equity - purchase of Fruitflow® II SD
29th Dec 202312:48 pmRNSHalf-year Report
26th Oct 20231:51 pmRNSResult of AGM
29th Sep 20237:00 amRNSFinal Results
30th Aug 20237:04 amRNSBYHEALTH regulatory filing with Chinese SAMR
3rd Apr 20237:00 amRNSCapital structure and funding update
24th Jan 202311:03 amRNSGrant of Share Options
30th Dec 20228:53 amRNSHalf-year Report
27th Oct 20221:12 pmRNSResult of AGM
14th Oct 20227:00 amRNSDirectorate Change
30th Sep 20227:00 amRNSFinal Results
22nd Jun 20227:00 amRNSTwo new agreements with DSM & patent application
31st May 20225:00 pmRNSTotal Voting Rights
17th May 202212:39 pmRNSExercise of Options and Total Voting Rights
31st Dec 20217:00 amRNSHalf-year Report
26th Nov 20214:41 pmRNSSecond Price Monitoring Extn
26th Nov 20214:36 pmRNSPrice Monitoring Extension
4th Nov 20211:30 pmRNSResult of AGM
4th Nov 202111:07 amRNSBy-Health Fruitflow agreement and support in R&D
1st Oct 20216:04 pmRNSGrant of Share Options
30th Sep 20217:00 amRNSFinal Results
9th Sep 20214:41 pmRNSSecond Price Monitoring Extn
9th Sep 20214:35 pmRNSPrice Monitoring Extension
24th Aug 20214:35 pmRNSPrice Monitoring Extension
22nd Jul 20214:40 pmRNSSecond Price Monitoring Extn
22nd Jul 20214:35 pmRNSPrice Monitoring Extension
21st Jul 20214:41 pmRNSSecond Price Monitoring Extn
21st Jul 20214:36 pmRNSPrice Monitoring Extension
5th Jul 20214:35 pmRNSPrice Monitoring Extension
1st Jul 20214:40 pmRNSSecond Price Monitoring Extn
1st Jul 20214:35 pmRNSPrice Monitoring Extension
26th Feb 20215:00 pmRNSTotal Voting Rights
19th Feb 20217:30 amRNSDirector / PDMR notification
19th Feb 20217:00 amRNSPlacing of new ordinary shares to raise £50,000
29th Jan 202112:37 pmRNSHalf-year Report
31st Dec 20201:00 pmRNSTotal Voting Rights
17th Dec 20207:00 amRNS£1m placing & update re HY results
16th Nov 20207:00 amRNSExclusive Distribution Agreement for Chinese CBEC
30th Oct 20202:09 pmRNSResult of AGM
30th Sep 20207:00 amRNSFinal Results
28th Aug 20205:00 pmRNSTotal Voting Rights
13th Aug 20207:00 amRNSFruitflow® & Blood Pressure - purchase of IP
7th Aug 20205:11 pmRNSHolding(s) in Company
27th May 20207:00 amRNSHolding(s) in Company
31st Dec 20197:13 amRNSInterim Results and Total Voting Rights
11th Dec 20197:00 amRNSPlacing of new ordinary shares to raise £0.301m
4th Oct 20191:19 pmRNSResult of AGM
12th Sep 20193:19 pmRNSDirector/PDMR Shareholding
11th Sep 20194:02 pmRNSGrant of Share Options
10th Sep 20197:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.